USHIFU, LLC Completes Acquisition of Focus Surgery, Inc.

    Combination Creates New Opportunities for Expansion of HIFU Technology

    CHARLOTTE, N.C., July 2 /CNW/ -- USHIFU, LLC (USHIFU), the distributor
and provider of non-invasive high intensity focused ultrasound for prostate
cancer, announced today that it has completed the acquisition of Focus
Surgery, Inc. (FSI) of Indianapolis, IN, the creator and manufacturer of the
Sonablate(R) 500, an image-guided acoustic ablation device. This acquisition
will accelerate USHIFU's ability to expand the FSI HIFU technology platform,
as well as gain access to new markets, such as India.
    "I speak for the combined USHIFU and Focus Surgery team when I say we are
thrilled to announce the acquisition of Focus Surgery.  Watching the
technological innovation that Focus Surgery scientists and engineers have
consistently achieved over the last several years with limited resources has
been nothing short of amazing," said Steve Puckett, Jr., CEO USHIFU.  "As a
much stronger combined entity we are more encouraged than ever about our
ability to positively affect healthcare delivery around the world."
    "A great milestone in the history of Focus Surgery, Inc. is achieved
today as it combines all its technological strength with USHIFU, LLC. The
combined Company will make HIFU rapidly available in approved markets
worldwide for the treatment of a most deadly disease - cancer, which is very
important," said Narendra Sanghvi, President, FSI.  "In addition, this is also
an extraordinary opportunity to quickly commercialize many of the advanced
HIFU applications to create a medical revolution with bloodless surgery while
maintaining high quality of life."
    About USHIFU, LLC
    USHIFU is a healthcare development company and medical device distributor
committed to creating a new standard for prostate cancer treatment with high
intensity focused ultrasound (HIFU) therapy. USHIFU works with hospitals and
medical centers in countries where HIFU is authorized for treating prostate
cancer, including Canada, Mexico, the Dominican Republic and the Bahamas, to
make the non invasive therapy available. USHIFU is also funding FDA-approved
clinical trials in the United States to gather data important for analysis of
the technology by the FDA.  The first is a pivotal trial for the treatment of
primary organ confined prostate cancer that will enroll 466 participants at 24
different centers.  A second pivotal trial will begin for the treatment of
recurrent prostate cancer in men who have failed external beam radiation
therapy.  This single arm study will enroll 202 participants at 10 different
    About the Sonablate(R) 500
    The Sonablate(R) 500 is a non-invasive medical device that utilizes
ultrasound energy to destroy tissue within the body. It was developed by FSI
and is manufactured by Misonix, Inc. (Nasdaq:   MSON) who also holds
distribution rights in Europe. Takai Hospital Supply Ltd. and THS
International distribute the Sonablate(R) 500 in Southeast Asia and the Middle
    The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R)
500 remains investigational in the U.S. and is being studied for the treatment
of prostate cancer in clinical trials in the U.S. FDA has made no decision as
to the safety or efficacy of the Sonablate(R) 500 for the treatment of
prostate cancer.

For further information:

For further information: Amanda Willis of USHIFU, LLC, +1-704-936-1823, Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890